BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024

Core Insights - BioNTech will present clinical trial data for its oncology pipeline at the ESMO Congress 2024 in Barcelona from September 13-17, 2024, focusing on mRNA-based cancer vaccines, immunomodulators, and targeted therapies [1][4] Clinical Trial Updates - The company will showcase updates on several Phase 2 and Phase 1/2 clinical trials evaluating BNT327/PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, in various cancer indications [3][4] - Preliminary data from ongoing trials for BNT113, an mRNA immunotherapy for HPV16-driven cancers, will demonstrate immunogenicity and antitumor activity in heavily pre-treated patients [3][4] - Data from a randomized Phase 2 trial of BNT316/ONC-392 in combination with pembrolizumab for platinum-resistant recurrent ovarian cancer will be presented in a late-breaking session [3][4] - Follow-up data on BNT211, a CAR-T cell therapy for CLDN6+ solid tumors, will show signs of antitumor activity and increased persistence of CAR-T cells when combined with an mRNA vaccine [3][4] Pipeline Overview - BioNTech has a diversified oncology pipeline with over 32 clinical trials, including eight in advanced Phase 2 and two in pivotal Phase 3 trials, aiming for ten or more registrational trials by the end of 2024 [4][7] - The company is developing a range of therapies, including mRNA-based vaccines, CAR-T cells, bispecific antibodies, and antibody-drug conjugates [7]